NO323754B1 - Anvendelse av en sammensetning som omfatter anti-(alfa-fetoproteinreseptor)-antistoff til a femstille et farmasoytisk preparat til a behandle kreft - Google Patents
Anvendelse av en sammensetning som omfatter anti-(alfa-fetoproteinreseptor)-antistoff til a femstille et farmasoytisk preparat til a behandle kreft Download PDFInfo
- Publication number
- NO323754B1 NO323754B1 NO19971256A NO971256A NO323754B1 NO 323754 B1 NO323754 B1 NO 323754B1 NO 19971256 A NO19971256 A NO 19971256A NO 971256 A NO971256 A NO 971256A NO 323754 B1 NO323754 B1 NO 323754B1
- Authority
- NO
- Norway
- Prior art keywords
- afp
- patient
- receptor
- antibodies
- cancer cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5757—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofoetal proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/92—Detection of biochemical
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Optics & Photonics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30814194A | 1994-09-19 | 1994-09-19 | |
| PCT/IB1995/000902 WO1996009551A1 (en) | 1994-09-19 | 1995-09-18 | Detection and treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO971256D0 NO971256D0 (no) | 1997-03-18 |
| NO971256L NO971256L (no) | 1997-03-18 |
| NO323754B1 true NO323754B1 (no) | 2007-07-02 |
Family
ID=23192727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19971256A NO323754B1 (no) | 1994-09-19 | 1997-03-18 | Anvendelse av en sammensetning som omfatter anti-(alfa-fetoproteinreseptor)-antistoff til a femstille et farmasoytisk preparat til a behandle kreft |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6514685B1 (de) |
| EP (3) | EP1956374A1 (de) |
| KR (1) | KR970706498A (de) |
| CN (2) | CN100472213C (de) |
| AT (1) | ATE449342T1 (de) |
| AU (1) | AU714966B2 (de) |
| BR (1) | BR9508959A (de) |
| CA (1) | CA2197490A1 (de) |
| DE (1) | DE69536019D1 (de) |
| DK (1) | DK0782709T3 (de) |
| ES (1) | ES2336976T3 (de) |
| FI (1) | FI121353B (de) |
| NO (1) | NO323754B1 (de) |
| RU (1) | RU2161042C2 (de) |
| WO (1) | WO1996009551A1 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115399B2 (en) * | 2001-07-31 | 2006-10-03 | Allergan, Inc. | Pinna reflex assay |
| WO2003060477A2 (en) * | 2002-01-10 | 2003-07-24 | The Regents Of The University Of California | Iterative optical based histology |
| US7638270B2 (en) * | 2003-01-24 | 2009-12-29 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 254P1D6B useful in treatment and detection of cancer |
| CN100360684C (zh) * | 2005-02-01 | 2008-01-09 | 合肥中科大生物技术有限公司 | 甲胎蛋白(AFP)mRNA荧光定量RT-PCR检测试剂盒 |
| EP2118123B1 (de) | 2007-01-31 | 2015-10-14 | Dana-Farber Cancer Institute, Inc. | Stabilisierte p53-peptide und deren verwendungen |
| EP2508531B1 (de) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Geheftete Polypeptide |
| RU2377962C1 (ru) * | 2008-06-10 | 2010-01-10 | Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко РАСХН(ВИЭВ) | Способ диагностики лейкоза крупного рогатого скота |
| BRPI0911926A2 (pt) | 2008-08-05 | 2020-08-18 | Toray Industries, Inc | composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo. |
| HUE027332T2 (en) | 2008-08-05 | 2016-09-28 | Toray Industries | Cancer Detection Method |
| US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
| US8968210B2 (en) * | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
| US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
| US9186128B2 (en) * | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
| US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
| CA2774973A1 (en) | 2009-09-22 | 2011-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| AU2010309438A1 (en) * | 2009-10-22 | 2012-06-07 | Ricardo J. Moro | Peptides that bind the alpha-fetoprotein (AFP) receptor and uses thereof |
| HUE040012T2 (hu) * | 2010-02-04 | 2019-02-28 | Toray Industries | Gyógyászati ágens rák kezelésére és/vagy megelõzésére |
| US8791121B2 (en) | 2010-08-12 | 2014-07-29 | New York University | Oligooxopiperazines and methods of making and using them |
| MX355543B (es) | 2010-08-13 | 2018-04-20 | Aileron Therapeutics Inc Star | Macrociclos peptidomiméticos. |
| DK2741085T3 (en) | 2011-08-04 | 2017-06-19 | Toray Industries | Method for detecting pancreatic cancer |
| MX358886B (es) | 2011-10-18 | 2018-08-31 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos. |
| CN104144695A (zh) | 2012-02-15 | 2014-11-12 | 爱勒让治疗公司 | 三唑交联的和硫醚交联的拟肽大环化合物 |
| CN107216380A (zh) | 2012-02-15 | 2017-09-29 | 爱勒让治疗公司 | 拟肽大环化合物 |
| CN104334541A (zh) | 2012-02-16 | 2015-02-04 | 纽约大学 | 使用低聚氧代哌嗪非肽螺旋模拟物对低氧诱导基因表达的控制 |
| US9772332B2 (en) | 2012-07-19 | 2017-09-26 | Toray Industries, Inc. | Method for detecting CAPRIN-1 in a biological sample |
| JP6526563B2 (ja) | 2012-11-01 | 2019-06-05 | エイルロン セラピューティクス,インコーポレイテッド | 二置換アミノ酸ならびにその調製および使用の方法 |
| DK3031826T3 (en) | 2013-08-09 | 2018-12-17 | Toray Industries | Pharmaceutical composition for the treatment and / or prevention of cancer |
| CN112972378A (zh) | 2014-09-24 | 2021-06-18 | 艾瑞朗医疗公司 | 拟肽大环化合物及其制剂 |
| AU2015320549A1 (en) | 2014-09-24 | 2017-04-13 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| KR20170129879A (ko) | 2015-03-20 | 2017-11-27 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
| US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| JP2018528217A (ja) | 2015-09-10 | 2018-09-27 | エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. | Mcl−1のモジュレーターとしてのペプチド模倣大環状分子 |
| WO2017079442A1 (en) | 2015-11-04 | 2017-05-11 | Icahn School Of Medicine At Mount Sinai | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment |
| WO2017189730A1 (en) | 2016-04-26 | 2017-11-02 | Icahn School Of Medicine At Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
| CN106290876B (zh) * | 2016-08-11 | 2018-06-29 | 湖南新大陆生物技术有限公司 | 一种肿瘤细胞检测方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2682697B2 (ja) | 1989-03-29 | 1997-11-26 | 積水化学工業株式会社 | 免疫測定試薬および免疫測定法 |
| FR2701710B1 (fr) * | 1993-02-18 | 1995-04-21 | Intromed Ltd | Conjugués protéiques, compositions les contenant et leurs applications en tant que médicament et réactif de diagnostic. |
-
1995
- 1995-09-18 AT AT95940906T patent/ATE449342T1/de not_active IP Right Cessation
- 1995-09-18 WO PCT/IB1995/000902 patent/WO1996009551A1/en not_active Ceased
- 1995-09-18 AU AU37648/95A patent/AU714966B2/en not_active Ceased
- 1995-09-18 RU RU97106059/14A patent/RU2161042C2/ru not_active IP Right Cessation
- 1995-09-18 DE DE69536019T patent/DE69536019D1/de not_active Expired - Lifetime
- 1995-09-18 CN CNB200310104769XA patent/CN100472213C/zh not_active Expired - Fee Related
- 1995-09-18 EP EP08002690A patent/EP1956374A1/de not_active Withdrawn
- 1995-09-18 BR BR9508959A patent/BR9508959A/pt not_active Application Discontinuation
- 1995-09-18 DK DK95940906.1T patent/DK0782709T3/da active
- 1995-09-18 EP EP95940906A patent/EP0782709B1/de not_active Expired - Lifetime
- 1995-09-18 KR KR1019970701775A patent/KR970706498A/ko not_active Ceased
- 1995-09-18 CN CN95195125A patent/CN1132012C/zh not_active Expired - Fee Related
- 1995-09-18 EP EP08002689A patent/EP1955714A1/de not_active Withdrawn
- 1995-09-18 ES ES95940906T patent/ES2336976T3/es not_active Expired - Lifetime
- 1995-09-18 CA CA002197490A patent/CA2197490A1/en not_active Abandoned
-
1997
- 1997-03-10 FI FI970990A patent/FI121353B/fi not_active IP Right Cessation
- 1997-03-18 NO NO19971256A patent/NO323754B1/no not_active IP Right Cessation
- 1997-08-15 US US08/920,654 patent/US6514685B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU714966B2 (en) | 2000-01-13 |
| CN1132012C (zh) | 2003-12-24 |
| BR9508959A (pt) | 1997-12-30 |
| EP0782709B1 (de) | 2009-11-18 |
| RU2161042C2 (ru) | 2000-12-27 |
| NO971256D0 (no) | 1997-03-18 |
| DK0782709T3 (da) | 2010-03-29 |
| ES2336976T3 (es) | 2010-04-19 |
| FI121353B (fi) | 2010-10-15 |
| WO1996009551A1 (en) | 1996-03-28 |
| NO971256L (no) | 1997-03-18 |
| EP1955714A1 (de) | 2008-08-13 |
| ATE449342T1 (de) | 2009-12-15 |
| AU3764895A (en) | 1996-04-09 |
| EP0782709A1 (de) | 1997-07-09 |
| CA2197490A1 (en) | 1996-03-28 |
| FI970990A7 (fi) | 1997-03-10 |
| FI970990A0 (fi) | 1997-03-10 |
| CN1502994A (zh) | 2004-06-09 |
| US6514685B1 (en) | 2003-02-04 |
| CN100472213C (zh) | 2009-03-25 |
| CN1169778A (zh) | 1998-01-07 |
| KR970706498A (ko) | 1997-11-03 |
| EP1956374A1 (de) | 2008-08-13 |
| DE69536019D1 (de) | 2009-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323754B1 (no) | Anvendelse av en sammensetning som omfatter anti-(alfa-fetoproteinreseptor)-antistoff til a femstille et farmasoytisk preparat til a behandle kreft | |
| AU2003235005B2 (en) | Antibodies to non-functional P2X7 receptor diagnosis and treatment of cancers and other conditions | |
| BRPI0909672B1 (pt) | método de imunoensaio in vitro para detecção da presença de células de câncer de fígado em um indivíduo, método para classificação de células de câncer de fígado presentes em um indivíduo, método in vitro para determinação de administrar ou não um agente anticâncer contendo um anticorpo anti-glipicano 3 a um indivíduo, e método in vitro para determinação de uma dose de um agente anticâncer contendo um anticorpo anti-glipicano 3 no tratamento de câncer de fígado em um indivíduo | |
| JPH05509308A (ja) | がん関連scm認織因子、その生成法および使用法 | |
| RU97106059A (ru) | Обнаружение и лечение рака | |
| JP5836940B2 (ja) | ソリシジン由来ペプチドならびにtrpv−6がんの検出および薬剤送達のための方法 | |
| WO1982004262A1 (en) | Detection of malignant tumor cells | |
| JPH06501469A (ja) | サイトケラチン断片の精製 | |
| EP1059944A1 (de) | Detektormolekül zur verwendung in einem verfahren zur anzeige und zur chirurgischen entfernung von lymphgewebe bei krebsbefall | |
| US20070237760A1 (en) | Detection and treatment of cancer | |
| Slade et al. | Localization and synthesis of α-fetoprotein in the chicken | |
| AU2007200062B2 (en) | Detection and treatment of cancer | |
| JPH11511847A (ja) | 癌の検出及び処理 | |
| AU2765400A (en) | Detection and treatment of cancer | |
| Gold | Tumor-specific antigen in GI cancer | |
| Vincendeau et al. | Bullous dermatosis and myeloma: Monoclonal anticytoplasmic antibody activity | |
| Wilson et al. | Laminin and type IV collagen in experimental rat oral carcinomas | |
| CN116726206A (zh) | 抗体偶联近红外ii区荧光探针、构建方法和应用 | |
| KR20250026610A (ko) | 종양 오가노이드 및 정상 오가노이드의 공배양을 이용한 항암제 스크리닝 방법 | |
| Engelhardt et al. | Immunization of guinea pigs with human choline acetyltransferase induces selective lower motoneuron destruction | |
| Reiter | Reg IV. A Candidate Marker of Hormone Refractory Metastatic Prostate Cancer | |
| Hohenboken | GLUCAGON-RELATED PEPTIDES IN THE CENTRAL NERVOUS SYSTEM. | |
| Chimienti | In vitro and in vivo studies of antibrain antibodies | |
| Russo | STRUCTURAL STUDIES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (ONCOGENES, SIGNAL TRANSDUCTION, TRANSMEMBRANE) | |
| HK1128478A (en) | Cytotoxicity mediation of cells evidencing surface expression of cd59 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |